首页 > 最新文献

Advances in Clinical and Experimental Medicine最新文献

英文 中文
Current role of intravascular imaging in percutaneous treatment of calcified coronary lesions. 血管内成像在经皮治疗冠状动脉钙化病变中的当前作用。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/175273
Oscar Rakotoarison, Tomasz Roleder, Wojciech Zimoch, Wiktor Kuliczkowski, Krzysztof Reczuch, Piotr Kübler

Percutaneous treatment of calcified coronary lesions is still a challenge in modern interventional cardiology practice. Coronary angiography is limited to the precise and quantitative assessment of calcium in coronary arteries. Intracoronary imaging (ICI) modalities, including optical coherence tomography (OCT) and intravascular ultrasound (IVUS), produce a very detailed image of calcifications and could help in proper percutaneous treatment. Intracoronary imaging indicates the need to use additional tools and improves the final effect of an intervention. Drawing on the already published literature, the authors focused on the qualification of patients to the procedure, conduct and result of interventional procedures involving calcified lesions supported by ICI. The article shows the advantages and disadvantages of both ICI methods in general and especially in calcified lesions. Currently available tools dedicated to dealing with coronary calcium and helping to meet optimal stent implantation criteria are also described. This article reviews the data on ICI implementation in daily clinical practice to improve the results of percutaneous interventions, and indicates further directions.

经皮治疗冠状动脉钙化病变仍然是现代介入心脏病学实践中的一项挑战。冠状动脉造影术仅限于对冠状动脉中的钙质进行精确的定量评估。冠状动脉内成像(ICI)模式,包括光学相干断层扫描(OCT)和血管内超声(IVUS),可生成非常详细的钙化图像,有助于正确的经皮治疗。冠状动脉内成像可显示是否需要使用其他工具,并改善介入治疗的最终效果。作者借鉴已发表的文献,重点探讨了患者的手术资质、在 ICI 支持下对钙化病变进行介入治疗的过程和结果。文章介绍了两种 ICI 方法的优缺点,尤其是在钙化病变中。文章还介绍了目前可用的专门用于处理冠状动脉钙化和帮助达到最佳支架植入标准的工具。本文回顾了在日常临床实践中实施 ICI 以改善经皮介入治疗效果的数据,并指出了进一步的方向。
{"title":"Current role of intravascular imaging in percutaneous treatment of calcified coronary lesions.","authors":"Oscar Rakotoarison, Tomasz Roleder, Wojciech Zimoch, Wiktor Kuliczkowski, Krzysztof Reczuch, Piotr Kübler","doi":"10.17219/acem/175273","DOIUrl":"10.17219/acem/175273","url":null,"abstract":"<p><p>Percutaneous treatment of calcified coronary lesions is still a challenge in modern interventional cardiology practice. Coronary angiography is limited to the precise and quantitative assessment of calcium in coronary arteries. Intracoronary imaging (ICI) modalities, including optical coherence tomography (OCT) and intravascular ultrasound (IVUS), produce a very detailed image of calcifications and could help in proper percutaneous treatment. Intracoronary imaging indicates the need to use additional tools and improves the final effect of an intervention. Drawing on the already published literature, the authors focused on the qualification of patients to the procedure, conduct and result of interventional procedures involving calcified lesions supported by ICI. The article shows the advantages and disadvantages of both ICI methods in general and especially in calcified lesions. Currently available tools dedicated to dealing with coronary calcium and helping to meet optimal stent implantation criteria are also described. This article reviews the data on ICI implementation in daily clinical practice to improve the results of percutaneous interventions, and indicates further directions.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1277-1287"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis. 乙酰胆碱酯酶抑制剂治疗阿尔茨海默病的安全性和有效性:系统回顾和荟萃分析。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/176051
Yaqi Gao, Yulin Liu, Yanfang Li

Alzheimer's disease (AD) affects millions of people worldwide. The most commonly used drugs are acetylcholinesterase inhibitors, i.e., donepezil, galantamine and rivastigmine, which increase levels of acetylcholine. However, the exact efficacy and safety of acetylcholinesterase inhibitors in the treatment of AD is still unclear. The main objective of the current study was to determine the exact safety and efficacy profile of acetylcholinesterase inhibitors in the treatment of AD by conducting a systematic review and meta-analysis of clinical trials according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We conducted a web-based literature search of PubMed and clinical trial websites using relevant keywords. Data were extracted from eligible records and pooled as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (95% CI) using Review Manager software (v. 5.3 for Windows). Heterogeneity was calculated using χ2 and I2 tests. The standard mean difference (SMD) was -0.33 [-0.52, -0.13] for donepezil, -0.48 [-0.58, -0.38] for galantamine and -0.65 [-1.06, -0.23] for rivastigmine, indicating a significant effect of these drugs on cognitive outcomes. Here we show the significant effects of all available acetylcholinesterase inhibitors on cognitive function in patients with AD. However, further studies are needed to draw valid conclusions about the effects of acetylcholinesterase inhibitors on functional outcomes and adverse events.

阿尔茨海默病(AD)影响着全球数百万人。最常用的药物是乙酰胆碱酯酶抑制剂,即多奈哌齐、加兰他敏和利伐斯的明,它们能提高乙酰胆碱的水平。然而,乙酰胆碱酯酶抑制剂在治疗注意力缺失症方面的确切疗效和安全性仍不明确。本研究的主要目的是根据系统综述和荟萃分析首选报告项目(Preferred Reporting Items for Systematic Reviews and Meta-Analyses,PRISMA)指南,通过对临床试验进行系统综述和荟萃分析,确定乙酰胆碱酯酶抑制剂治疗AD的确切安全性和疗效。我们使用相关关键词对 PubMed 和临床试验网站进行了网络文献检索。从符合条件的记录中提取数据,并使用 Review Manager 软件(Windows 版 5.3)以平均差 (MD) 或风险比 (RR) 值及其 95% 置信区间 (95% CI) 的形式进行汇总。异质性采用χ2和I2检验进行计算。多奈哌齐的标准平均差(SMD)为-0.33 [-0.52, -0.13],加兰他敏为-0.48 [-0.58, -0.38],利伐斯的明为-0.65 [-1.06, -0.23],表明这些药物对认知结果有显著影响。在此,我们展示了所有可用的乙酰胆碱酯酶抑制剂对 AD 患者认知功能的显著影响。然而,要就乙酰胆碱酯酶抑制剂对功能预后和不良事件的影响得出有效结论,还需要进一步的研究。
{"title":"Safety and efficacy of acetylcholinesterase inhibitors for Alzheimer's disease: A systematic review and meta-analysis.","authors":"Yaqi Gao, Yulin Liu, Yanfang Li","doi":"10.17219/acem/176051","DOIUrl":"10.17219/acem/176051","url":null,"abstract":"<p><p>Alzheimer's disease (AD) affects millions of people worldwide. The most commonly used drugs are acetylcholinesterase inhibitors, i.e., donepezil, galantamine and rivastigmine, which increase levels of acetylcholine. However, the exact efficacy and safety of acetylcholinesterase inhibitors in the treatment of AD is still unclear. The main objective of the current study was to determine the exact safety and efficacy profile of acetylcholinesterase inhibitors in the treatment of AD by conducting a systematic review and meta-analysis of clinical trials according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We conducted a web-based literature search of PubMed and clinical trial websites using relevant keywords. Data were extracted from eligible records and pooled as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (95% CI) using Review Manager software (v. 5.3 for Windows). Heterogeneity was calculated using χ2 and I2 tests. The standard mean difference (SMD) was -0.33 [-0.52, -0.13] for donepezil, -0.48 [-0.58, -0.38] for galantamine and -0.65 [-1.06, -0.23] for rivastigmine, indicating a significant effect of these drugs on cognitive outcomes. Here we show the significant effects of all available acetylcholinesterase inhibitors on cognitive function in patients with AD. However, further studies are needed to draw valid conclusions about the effects of acetylcholinesterase inhibitors on functional outcomes and adverse events.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1179-1187"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic encephalopathies in children: A pragmatic diagnostic approach based on literature analysis. 儿童代谢性脑病:基于文献分析的实用诊断方法。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/175809
Dariusz Rokicki

Inborn errors of metabolism (IEM) in the general population are rare diseases. However, from the perspective of general pediatrics and pediatric intensive care units (PICUs), they are becoming a significant challenge both diagnostically and therapeutically. Clinically, there is a useful division of IEMs with neurological manifestations into 2 categories: acute and progressive encephalopathies. The extent of individual IEMs in these 2 groups varies, requiring different diagnostic strategies. Despite progress in development of diagnostic tools in IEM, initial diagnosis is made on the basis of basic laboratory tests, neuroradiological findings and metabolic screening. In settings of shortage of diagnostic resources and under time pressure, rational decisions should be made based on available clinical data. The text discusses diagnostic aspects of IEM presenting as metabolic encephalopathies, highlighting their significance in the context of general pediatric care and intensive care units (ICUs), and the challenges associated with diagnosis. It should be noted that the paper does not include a discussion of epileptic encephalopathies of IEM etiology, although some cases of metabolic encephalopathies may also present initially as epileptic encephalopathy.

先天性代谢异常(IEM)在普通人群中属于罕见病。然而,从普通儿科和儿科重症监护室(PICU)的角度来看,它们正成为诊断和治疗方面的重大挑战。在临床上,有神经系统表现的 IEM 可分为两类:急性和进行性脑病。这两类 IEM 的程度各不相同,因此需要不同的诊断策略。尽管在 IEM 诊断工具的开发方面取得了进展,但初步诊断仍以基本实验室检测、神经放射学检查结果和代谢筛查为基础。在诊断资源短缺和时间紧迫的情况下,应根据现有的临床数据做出合理的决定。文中讨论了表现为代谢性脑病的 IEM 的诊断问题,强调了其在普通儿科护理和重症监护病房(ICU)中的重要性,以及与诊断相关的挑战。需要注意的是,本文不包括对 IEM 病因的癫痫性脑病的讨论,尽管某些代谢性脑病病例最初也可能表现为癫痫性脑病。
{"title":"Metabolic encephalopathies in children: A pragmatic diagnostic approach based on literature analysis.","authors":"Dariusz Rokicki","doi":"10.17219/acem/175809","DOIUrl":"10.17219/acem/175809","url":null,"abstract":"<p><p>Inborn errors of metabolism (IEM) in the general population are rare diseases. However, from the perspective of general pediatrics and pediatric intensive care units (PICUs), they are becoming a significant challenge both diagnostically and therapeutically. Clinically, there is a useful division of IEMs with neurological manifestations into 2 categories: acute and progressive encephalopathies. The extent of individual IEMs in these 2 groups varies, requiring different diagnostic strategies. Despite progress in development of diagnostic tools in IEM, initial diagnosis is made on the basis of basic laboratory tests, neuroradiological findings and metabolic screening. In settings of shortage of diagnostic resources and under time pressure, rational decisions should be made based on available clinical data. The text discusses diagnostic aspects of IEM presenting as metabolic encephalopathies, highlighting their significance in the context of general pediatric care and intensive care units (ICUs), and the challenges associated with diagnosis. It should be noted that the paper does not include a discussion of epileptic encephalopathies of IEM etiology, although some cases of metabolic encephalopathies may also present initially as epileptic encephalopathy.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1259-1265"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139690967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Depressive disorders in children with chronic kidney disease treated conservatively. 接受保守治疗的慢性肾病患儿的抑郁障碍。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/175236
Katarzyna Kiliś-Pstrusińska, Anna Medyńska, Piotr Adamczyk, Beata Leszczyńska, Maria Szczepańska, Marcin Tkaczyk, Anna M Wasilewska, Katarzyna Zachwieja, Ilona Zagożdżon, Krzysztof Kujawa, Natalia W Dryjańska

Background: Children with chronic kidney disease (CKD) experience a lot of mental and emotional stress, which can lead to the development of depressive disorders. The prevalence of depressive disorders in CKD children is estimated to be between 7% and 35%.

Objectives: The aim of our study was to analyze the prevalence and characteristics of depression and depressive symptoms in children and adolescents with CKD treated conservatively.

Material and methods: The cross-sectional, multicenter study was conducted in 73 CKD children aged 8-18 and in 92 of their parents. To assess the mental wellbeing of CKD children, Kovacs's Children's Depression Inventory 2 (CDI2) was used as CDI2: Self-Report and CDI2: Parent Form.

Results: The majority of CKD children acquired medium scores in CDI2, 11% of participants reported symptoms suggesting depressive disorder, and among them 8.2% met the criteria for depression. A significant relationship was found between age and interpersonal problems, age at CKD diagnosis, and total score and ineffectiveness, CKD duration and total score/emotional problems. Depressive symptoms were associated with the stage of CKD, and they differed significantly between stages III and IV. We noticed the child-parent disagreement on reported depressive symptoms. Parents perceive their children's mental state as worse than the children themselves.

Conclusions: There is a problem of depression in children with CKD treated conservatively. Variables associated with depressive symptoms in CKD children treated conservatively require further study. Key factors predisposing to the development of depression seem to be age at the time of diagnosis, disease duration, and progression of CKD from stage III to IV. Disparities between depressive symptoms self-reported by CKD children and their parents' assessment require further analysis. However, these disparaties indicate that the final diagnosis of the occurrence of depressive disorders should be based on a multidimensional assessment of the patient's situation.

背景:患有慢性肾脏病(CKD)的儿童承受着巨大的精神和情绪压力,这可能导致抑郁症的发生。据估计,慢性肾脏病儿童抑郁症的发病率在 7% 至 35% 之间:我们的研究旨在分析接受保守治疗的 CKD 儿童和青少年中抑郁症和抑郁症状的患病率和特征:这项横断面多中心研究对 73 名 8-18 岁的 CKD 儿童及其 92 名父母进行了调查。为了评估 CKD 儿童的心理健康状况,采用了 Kovacs 的儿童抑郁量表 2(CDI2),即 CDI2:自我报告表和 CDI2:家长表:大多数 CKD 儿童在 CDI2 中获得中等分数,11% 的参与者报告了抑郁症状,其中 8.2% 符合抑郁症标准。研究发现,年龄与人际关系问题、CKD 诊断年龄、总分与无效性、CKD 病程和总分/情绪问题之间存在明显关系。抑郁症状与 CKD 的分期有关,在 III 期和 IV 期之间差异很大。我们注意到儿童和家长在报告抑郁症状方面存在分歧。父母认为孩子的精神状态比孩子自己更差:结论:接受保守治疗的慢性肾脏病患儿存在抑郁问题。结论:保守治疗的慢性肾脏病患儿中存在抑郁问题,与保守治疗的慢性肾脏病患儿抑郁症状相关的变量需要进一步研究。诊断时的年龄、病程以及 CKD 从 III 期进展到 IV 期似乎是导致抑郁症发生的关键因素。CKD 患儿自我报告的抑郁症状与其父母的评估之间的差异需要进一步分析。不过,这些差异表明,抑郁症的最终诊断应基于对患者情况的多维度评估。
{"title":"Depressive disorders in children with chronic kidney disease treated conservatively.","authors":"Katarzyna Kiliś-Pstrusińska, Anna Medyńska, Piotr Adamczyk, Beata Leszczyńska, Maria Szczepańska, Marcin Tkaczyk, Anna M Wasilewska, Katarzyna Zachwieja, Ilona Zagożdżon, Krzysztof Kujawa, Natalia W Dryjańska","doi":"10.17219/acem/175236","DOIUrl":"10.17219/acem/175236","url":null,"abstract":"<p><strong>Background: </strong>Children with chronic kidney disease (CKD) experience a lot of mental and emotional stress, which can lead to the development of depressive disorders. The prevalence of depressive disorders in CKD children is estimated to be between 7% and 35%.</p><p><strong>Objectives: </strong>The aim of our study was to analyze the prevalence and characteristics of depression and depressive symptoms in children and adolescents with CKD treated conservatively.</p><p><strong>Material and methods: </strong>The cross-sectional, multicenter study was conducted in 73 CKD children aged 8-18 and in 92 of their parents. To assess the mental wellbeing of CKD children, Kovacs's Children's Depression Inventory 2 (CDI2) was used as CDI2: Self-Report and CDI2: Parent Form.</p><p><strong>Results: </strong>The majority of CKD children acquired medium scores in CDI2, 11% of participants reported symptoms suggesting depressive disorder, and among them 8.2% met the criteria for depression. A significant relationship was found between age and interpersonal problems, age at CKD diagnosis, and total score and ineffectiveness, CKD duration and total score/emotional problems. Depressive symptoms were associated with the stage of CKD, and they differed significantly between stages III and IV. We noticed the child-parent disagreement on reported depressive symptoms. Parents perceive their children's mental state as worse than the children themselves.</p><p><strong>Conclusions: </strong>There is a problem of depression in children with CKD treated conservatively. Variables associated with depressive symptoms in CKD children treated conservatively require further study. Key factors predisposing to the development of depression seem to be age at the time of diagnosis, disease duration, and progression of CKD from stage III to IV. Disparities between depressive symptoms self-reported by CKD children and their parents' assessment require further analysis. However, these disparaties indicate that the final diagnosis of the occurrence of depressive disorders should be based on a multidimensional assessment of the patient's situation.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1189-1199"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139401334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioavailability of ursolic/oleanolic acid, with therapeutic potential in chronic diseases and cancer. 熊果酸/油醇酸的生物利用率,具有治疗慢性疾病和癌症的潜力。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/194013
Vasile Staicu, Justinian-Andrei Tomescu, Ioan Calinescu

This study focused on describing the bioavailability of ursolic/oleanolic acids (UA/OA) and the methods to increase it, so that these 2 bioactive compounds can have therapeutic and preventive effects in chronic diseases and cancer. Ursolic/oleanolic acids are natural compounds that have been known since the 19th century. They are very widespread and offer special benefits for human health - especially that their high absorbability makes them suitable for use in therapeutic and preventive treatment. One of the important aspects of their bioavailability is related to their interaction with other bioactive compounds or drugs. In chronic diseases and cancer, UA/OA may affect the absorption of other nutrients and interact with bioactive compounds. By increasing the bioavailability of UA/OA with various technical processes, especially using nanocarriers and nanoparticles, these compounds can affect collagen production, contributing to maintaining skin elasticity and preventing the appearance of wrinkles. Today, UA/OA are frequently used to treat many conditions, ranging from chronic to metabolic.

这项研究的重点是描述熊果酸/油菜醇酸(UA/OA)的生物利用率以及提高其生物利用率的方法,从而使这两种生物活性化合物对慢性疾病和癌症具有治疗和预防作用。熊果酸/油菜醇酸是一种天然化合物,早在 19 世纪就已为人所知。它们非常普遍,对人体健康有特殊的益处,尤其是它们的高吸收性使其适合用于治疗和预防。它们的生物利用率的一个重要方面与它们与其他生物活性化合物或药物的相互作用有关。在慢性疾病和癌症中,UA/OA 可能会影响其他营养素的吸收,并与生物活性化合物相互作用。通过各种技术工艺,特别是使用纳米载体和纳米颗粒来提高 UA/OA 的生物利用率,这些化合物可以影响胶原蛋白的生成,有助于保持皮肤弹性和防止皱纹的出现。如今,UA/OA 常用于治疗多种疾病,包括慢性病和代谢性疾病。
{"title":"Bioavailability of ursolic/oleanolic acid, with therapeutic potential in chronic diseases and cancer.","authors":"Vasile Staicu, Justinian-Andrei Tomescu, Ioan Calinescu","doi":"10.17219/acem/194013","DOIUrl":"10.17219/acem/194013","url":null,"abstract":"<p><p>This study focused on describing the bioavailability of ursolic/oleanolic acids (UA/OA) and the methods to increase it, so that these 2 bioactive compounds can have therapeutic and preventive effects in chronic diseases and cancer. Ursolic/oleanolic acids are natural compounds that have been known since the 19th century. They are very widespread and offer special benefits for human health - especially that their high absorbability makes them suitable for use in therapeutic and preventive treatment. One of the important aspects of their bioavailability is related to their interaction with other bioactive compounds or drugs. In chronic diseases and cancer, UA/OA may affect the absorption of other nutrients and interact with bioactive compounds. By increasing the bioavailability of UA/OA with various technical processes, especially using nanocarriers and nanoparticles, these compounds can affect collagen production, contributing to maintaining skin elasticity and preventing the appearance of wrinkles. Today, UA/OA are frequently used to treat many conditions, ranging from chronic to metabolic.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1173-1178"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of different treatment regimens and analysis of prognostic factors in secondary hemophagocytic lymphohistiocytosis in adults: A single-center retrospective study. 成人继发性嗜血细胞淋巴组织细胞增多症不同治疗方案的比较及预后因素分析:单中心回顾性研究。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/175355
Xing Wu, Changfeng Man, Wanying Cheng, Guangli Yin, Jiayu Huang, Jujuan Wang, Xin Gao, Tian Tian, Limin Duan, Ji Xu, Hongxia Qiu

Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease caused by immune hyperactivation. The overall survival (OS) of adults with secondary HLH remains suboptimal and new treatment strategies are needed.

Objectives: This study aimed to compare the efficacy of different regimens in the treatment of secondary HLH in adults and analyze the prognostic factors affecting patient survival.

Material and methods: The clinical data of 245 adults with secondary HLH admitted to our hospital from January 2016 to October 2021 were analyzed retrospectively. The patients were divided into 3 groups according to different treatment regimens: corticosteroids therapy + chemotherapy + supportive treatment group (JHZ group), chemotherapy + supportive treatment group (HZ group) and corticosteroids therapy + supportive treatment group (JZ group). The clinical efficacy was compared among the 3 groups after treatment, and progression-free survival (PFS) and overall survival (OS) were calculated. Additionally, risk factors associated with prognosis were also analyzed with Cox regression analysis.

Results: The objective response rate (ORR) in the JHZ group was higher than that in the HZ group and JZ group, but there was no significant difference between the 3 groups. Also, the patients in the JHZ group had the longest OS and median PFS. Further Cox regression analysis suggested that hyperbilirubinemia was an independent risk factor for OS in secondary HLH patients.

Conclusions: A combination of corticosteroids therapy, chemotherapy and supportive therapy is superior to the other 2 regimens in the clinical benefit in the treatment of secondary HLH in adults, and thus may be a preferred and feasible treatment regimen. Moreover, hyperbilirubinemia was a risk factor for prognosis that has crucial guiding significance for clinical treatment of patients with secondary HLH.

背景:嗜血细胞淋巴组织细胞增多症(HLH嗜血细胞淋巴组织细胞增多症(HLH)是一种因免疫功能亢进而导致的危及生命的疾病。继发性HLH成人患者的总生存率(OS)仍不理想,需要新的治疗策略:本研究旨在比较不同方案治疗成人继发性 HLH 的疗效,并分析影响患者生存的预后因素:回顾性分析我院2016年1月至2021年10月收治的245例成人继发性HLH患者的临床资料。根据不同的治疗方案将患者分为3组:皮质类固醇治疗+化疗+支持治疗组(JHZ组)、化疗+支持治疗组(HZ组)和皮质类固醇治疗+支持治疗组(JZ组)。比较三组治疗后的临床疗效,并计算无进展生存期(PFS)和总生存期(OS)。此外,还对与预后相关的危险因素进行了Cox回归分析:结果:JHZ组的客观反应率(ORR)高于HZ组和JZ组,但3组间无显著差异。此外,JHZ组患者的OS和中位PFS最长。进一步的Cox回归分析表明,高胆红素血症是继发性HLH患者OS的独立危险因素:结论:在治疗成人继发性 HLH 时,皮质类固醇疗法、化疗和支持疗法的联合应用在临床疗效上优于其他两种方案,因此可能是一种首选且可行的治疗方案。此外,高胆红素血症是影响预后的一个危险因素,对继发性 HLH 患者的临床治疗具有重要的指导意义。
{"title":"Comparison of different treatment regimens and analysis of prognostic factors in secondary hemophagocytic lymphohistiocytosis in adults: A single-center retrospective study.","authors":"Xing Wu, Changfeng Man, Wanying Cheng, Guangli Yin, Jiayu Huang, Jujuan Wang, Xin Gao, Tian Tian, Limin Duan, Ji Xu, Hongxia Qiu","doi":"10.17219/acem/175355","DOIUrl":"10.17219/acem/175355","url":null,"abstract":"<p><strong>Background: </strong>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease caused by immune hyperactivation. The overall survival (OS) of adults with secondary HLH remains suboptimal and new treatment strategies are needed.</p><p><strong>Objectives: </strong>This study aimed to compare the efficacy of different regimens in the treatment of secondary HLH in adults and analyze the prognostic factors affecting patient survival.</p><p><strong>Material and methods: </strong>The clinical data of 245 adults with secondary HLH admitted to our hospital from January 2016 to October 2021 were analyzed retrospectively. The patients were divided into 3 groups according to different treatment regimens: corticosteroids therapy + chemotherapy + supportive treatment group (JHZ group), chemotherapy + supportive treatment group (HZ group) and corticosteroids therapy + supportive treatment group (JZ group). The clinical efficacy was compared among the 3 groups after treatment, and progression-free survival (PFS) and overall survival (OS) were calculated. Additionally, risk factors associated with prognosis were also analyzed with Cox regression analysis.</p><p><strong>Results: </strong>The objective response rate (ORR) in the JHZ group was higher than that in the HZ group and JZ group, but there was no significant difference between the 3 groups. Also, the patients in the JHZ group had the longest OS and median PFS. Further Cox regression analysis suggested that hyperbilirubinemia was an independent risk factor for OS in secondary HLH patients.</p><p><strong>Conclusions: </strong>A combination of corticosteroids therapy, chemotherapy and supportive therapy is superior to the other 2 regimens in the clinical benefit in the treatment of secondary HLH in adults, and thus may be a preferred and feasible treatment regimen. Moreover, hyperbilirubinemia was a risk factor for prognosis that has crucial guiding significance for clinical treatment of patients with secondary HLH.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1201-1208"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139690966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BVES-AS1 suppresses the colorectal cancer progression via the miR-1269a/b-SVEP1-PI3K/AKT axis. BVES-AS1 通过 miR-1269a/b-SVEP1-PI3K/AKT 轴抑制结直肠癌的进展。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/175050
Jianguo Yang, Qican Deng, Zhenzhou Chen, Yajun Chen, Zhongxue Fu

Background: Numerous studies have indicated the engagement of long non-coding RNA (lncRNA) in various cancer types, including colorectal cancer (CRC). However, the functional and mechanistic roles of lncRNAs in CRC remain largely elusive.

Objectives: The aim of this study was to explore the function and mechanism of lncRNA BVES-AS1 in CRC.

Material and methods: The expression levels of BVES-AS1 were validated in CRC tissues and paired normal samples using quantitative real-time polymerase chain reaction (qPCR) Subsequently, the biological functions of BVES-AS1 in CRC cells were investigated both in vitro and in vivo. Various experimental techniques such as western blot, fluorescence in situ hybridization, RNA-sequencing (RNA-seq), biotin-labeled miRNA pulldown assay, dual-luciferase reporter gene assay, and RNA-protein immunoprecipitation (RIP) assay were employed to elucidate the potential mechanism of BVES-AS1.

Results: The findings of this study demonstrated that BVES-AS1 expression was downregulated in CRC tissues compared to normal tissues, and its expression level was associated with tumor infiltration and tumor-nodule-metastasis (TNM) stage. Furthermore, BVES-AS1 was found to suppress CRC cell proliferation, migration and metastasis both in vitro and in vivo. Mechanistically, BVES-AS1 acted as a sponge for miR-1269a and miR-1269b, thereby regulating SVEP1. Additionally, the silencing of SVEP1 activated the PI3K/AKT pathway.

Conclusions: These results suggest that BVES-AS1 plays a crucial role in the progression of CRC through the miR-1269a/b-SVEP1-PI3K/AKT axis, providing new insights into the therapeutic strategies for CRC.

背景:大量研究表明,长非编码RNA(lncRNA)参与了包括结直肠癌(CRC)在内的各种癌症类型。然而,lncRNA 在 CRC 中的功能和机理作用在很大程度上仍不明确:本研究旨在探讨 lncRNA BVES-AS1 在 CRC 中的功能和作用机制:采用实时定量聚合酶链式反应(qPCR)对BVES-AS1在CRC组织和配对正常样本中的表达水平进行了验证,随后在体外和体内对BVES-AS1在CRC细胞中的生物学功能进行了研究。研究采用了Western印迹、荧光原位杂交、RNA测序(RNA-seq)、生物素标记的miRNA pulldown检测、双荧光素酶报告基因检测和RNA-蛋白免疫沉淀(RIP)检测等多种实验技术,以阐明BVES-AS1的潜在作用机制:结果:研究结果表明,与正常组织相比,BVES-AS1在CRC组织中表达下调,其表达水平与肿瘤浸润和肿瘤-结节-转移(TNM)分期相关。此外,研究还发现 BVES-AS1 在体外和体内均能抑制 CRC 细胞的增殖、迁移和转移。从机理上讲,BVES-AS1 是 miR-1269a 和 miR-1269b 的海绵,从而调节 SVEP1。此外,SVEP1 的沉默激活了 PI3K/AKT 通路:这些结果表明,BVES-AS1通过miR-1269a/b-SVEP1-PI3K/AKT轴在CRC的进展中起着至关重要的作用,为CRC的治疗策略提供了新的见解。
{"title":"BVES-AS1 suppresses the colorectal cancer progression via the miR-1269a/b-SVEP1-PI3K/AKT axis.","authors":"Jianguo Yang, Qican Deng, Zhenzhou Chen, Yajun Chen, Zhongxue Fu","doi":"10.17219/acem/175050","DOIUrl":"10.17219/acem/175050","url":null,"abstract":"<p><strong>Background: </strong>Numerous studies have indicated the engagement of long non-coding RNA (lncRNA) in various cancer types, including colorectal cancer (CRC). However, the functional and mechanistic roles of lncRNAs in CRC remain largely elusive.</p><p><strong>Objectives: </strong>The aim of this study was to explore the function and mechanism of lncRNA BVES-AS1 in CRC.</p><p><strong>Material and methods: </strong>The expression levels of BVES-AS1 were validated in CRC tissues and paired normal samples using quantitative real-time polymerase chain reaction (qPCR) Subsequently, the biological functions of BVES-AS1 in CRC cells were investigated both in vitro and in vivo. Various experimental techniques such as western blot, fluorescence in situ hybridization, RNA-sequencing (RNA-seq), biotin-labeled miRNA pulldown assay, dual-luciferase reporter gene assay, and RNA-protein immunoprecipitation (RIP) assay were employed to elucidate the potential mechanism of BVES-AS1.</p><p><strong>Results: </strong>The findings of this study demonstrated that BVES-AS1 expression was downregulated in CRC tissues compared to normal tissues, and its expression level was associated with tumor infiltration and tumor-nodule-metastasis (TNM) stage. Furthermore, BVES-AS1 was found to suppress CRC cell proliferation, migration and metastasis both in vitro and in vivo. Mechanistically, BVES-AS1 acted as a sponge for miR-1269a and miR-1269b, thereby regulating SVEP1. Additionally, the silencing of SVEP1 activated the PI3K/AKT pathway.</p><p><strong>Conclusions: </strong>These results suggest that BVES-AS1 plays a crucial role in the progression of CRC through the miR-1269a/b-SVEP1-PI3K/AKT axis, providing new insights into the therapeutic strategies for CRC.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1217-1236"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139490624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B10 cells: Development, phenotype, and function in cancer. B10 细胞:癌症中的发育、表型和功能。
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/176378
Dandan Li, Yunfeng Ma

B10 cells, a specialized subset of regulatory B cells, have been identified in both mice and humans. These cells are characterized by their regulatory impact on immune dynamics, principally through their secretion of interleukin-10 (IL-10), a cytokine known for its anti-inflammatory properties. The pivotal role of immune mediators such as B10 cells is to maintain a delicate equilibrium between antitumor immunity and tumor-promoting responses. Emerging studies have cast B10 cells as key suppressors in the antitumor immune arsenal. They operate in synergy with a spectrum of immune cells within the innate and adaptive spectrums, contributing to a milieu that favors tumor progression and metastatic spread. In this comprehensive review, we will discuss the ontogeny, phenotype and effector functions of B10 cells in murine systems. We will also review the role of B10 cells in oncological models in animal studies and extend these findings to the human clinical context, elucidating their role in facilitating tumor immune evasion. A thorough understanding of these processes is imperative for the strategic targeting and attenuation of B10 cell activity, which is anticipated to be a cornerstone in the advancement of effective cancer immunotherapy strategies.

B10 细胞是调节性 B 细胞的一个特殊亚群,已在小鼠和人类中发现。这些细胞主要通过分泌白细胞介素-10(IL-10)这种具有抗炎特性的细胞因子对免疫动态产生调节作用。B10 细胞等免疫介质的关键作用是维持抗肿瘤免疫和肿瘤促进反应之间的微妙平衡。最新研究表明,B10 细胞是抗肿瘤免疫武器库中的关键抑制因子。它们与先天性和适应性免疫细胞协同作用,促成了有利于肿瘤进展和转移扩散的环境。在这篇综述中,我们将讨论小鼠系统中 B10 细胞的本体、表型和效应功能。我们还将回顾 B10 细胞在肿瘤模型动物研究中的作用,并将这些发现延伸到人类临床环境中,阐明它们在促进肿瘤免疫逃避中的作用。透彻了解这些过程对于战略性地瞄准和削弱 B10 细胞的活性至关重要,这有望成为推进有效癌症免疫疗法策略的基石。
{"title":"B10 cells: Development, phenotype, and function in cancer.","authors":"Dandan Li, Yunfeng Ma","doi":"10.17219/acem/176378","DOIUrl":"10.17219/acem/176378","url":null,"abstract":"<p><p>B10 cells, a specialized subset of regulatory B cells, have been identified in both mice and humans. These cells are characterized by their regulatory impact on immune dynamics, principally through their secretion of interleukin-10 (IL-10), a cytokine known for its anti-inflammatory properties. The pivotal role of immune mediators such as B10 cells is to maintain a delicate equilibrium between antitumor immunity and tumor-promoting responses. Emerging studies have cast B10 cells as key suppressors in the antitumor immune arsenal. They operate in synergy with a spectrum of immune cells within the innate and adaptive spectrums, contributing to a milieu that favors tumor progression and metastatic spread. In this comprehensive review, we will discuss the ontogeny, phenotype and effector functions of B10 cells in murine systems. We will also review the role of B10 cells in oncological models in animal studies and extend these findings to the human clinical context, elucidating their role in facilitating tumor immune evasion. A thorough understanding of these processes is imperative for the strategic targeting and attenuation of B10 cell activity, which is anticipated to be a cornerstone in the advancement of effective cancer immunotherapy strategies.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1247-1258"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139690964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parthenolide induces ROS-dependent cell death in human gastric cancer cell. 帕氏内酯诱导人胃癌细胞发生 ROS 依赖性细胞死亡
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/175152
Dandan Han, Wenhao Zhu, Yang Chen, Huiru Wang

Background: Parthenolide (PN), a key active ingredient of feverfew, has been used to treat gastrointestinal disorders. However, the mechanism of the cytotoxic effect exerted by PN on tumor cells has not been elucidated.

Objectives: To study the cytotoxic effect of PN on human gastric cancer cells, the specific death mode, and gene expression changes induced by PN.

Material and methods: In this study, MGC-803 cells were used to study PN-induced cytotoxicity as a gastric cancer cell line. Assays of cell proliferation, cell cycle distribution, apoptosis, and reactive oxygen species (ROS) were performed using a Cell Counting Kit-8 (CCK-8) assay and a flow cytometer. MGC-803 cells treated with and without PN were separately subjected to high-throughput RNA sequencing. Western blotting was used to investigate the expression of some important proteins.

Results: Parthenolide exposure elicited cell proliferation inhibition in a doseand time-dependent manner. Parthenolide induced cell cycle arrest at the G1 and S stages. Parthenolide-induced caspase-dependent apoptosis and necroptosis were caused by the activation of RIP, RIP3 and MLKL. MGC-803 cells showed a response to ROS and oxidative stress after PN treatment. Moreover, ROS and cytotoxicity induced by PN were significantly attenuated by a ROS scavenger catalase.

Conclusions: Parthenolide-induced gastric cancer cell death is a complex ROS-dependent process different from ordinary apoptosis and necrosis, suggesting that PN is a potential treatment option for gastric cancer.

背景:马钱子内酯(Parthenolide,PN)是马钱子的一种主要活性成分,已被用于治疗胃肠道疾病。然而,PN 对肿瘤细胞产生细胞毒性作用的机制尚未阐明:研究 PN 对人胃癌细胞的细胞毒性作用、特异性死亡模式以及 PN 诱导的基因表达变化:本研究以 MGC-803 细胞作为胃癌细胞系,研究 PN 诱导的细胞毒性。使用细胞计数试剂盒-8(CCK-8)和流式细胞仪对细胞增殖、细胞周期分布、细胞凋亡和活性氧(ROS)进行检测。使用和不使用 PN 处理的 MGC-803 细胞分别进行了高通量 RNA 测序。用 Western 印迹法检测了一些重要蛋白质的表达:结果:帕氏内酯暴露以剂量和时间依赖性方式抑制细胞增殖。帕氏内酯诱导细胞周期停滞在 G1 和 S 阶段。Parthenolide诱导的树突酶依赖性凋亡和坏死是由RIP、RIP3和MLKL激活引起的。经 PN 处理后,MGC-803 细胞出现了对 ROS 和氧化应激的反应。此外,ROS清除剂过氧化氢酶能显著减轻PN诱导的ROS和细胞毒性:结论:帕氏内酯诱导的胃癌细胞死亡是一个复杂的 ROS 依赖性过程,不同于普通的细胞凋亡和坏死,这表明帕氏内酯是一种潜在的胃癌治疗选择。
{"title":"Parthenolide induces ROS-dependent cell death in human gastric cancer cell.","authors":"Dandan Han, Wenhao Zhu, Yang Chen, Huiru Wang","doi":"10.17219/acem/175152","DOIUrl":"10.17219/acem/175152","url":null,"abstract":"<p><strong>Background: </strong>Parthenolide (PN), a key active ingredient of feverfew, has been used to treat gastrointestinal disorders. However, the mechanism of the cytotoxic effect exerted by PN on tumor cells has not been elucidated.</p><p><strong>Objectives: </strong>To study the cytotoxic effect of PN on human gastric cancer cells, the specific death mode, and gene expression changes induced by PN.</p><p><strong>Material and methods: </strong>In this study, MGC-803 cells were used to study PN-induced cytotoxicity as a gastric cancer cell line. Assays of cell proliferation, cell cycle distribution, apoptosis, and reactive oxygen species (ROS) were performed using a Cell Counting Kit-8 (CCK-8) assay and a flow cytometer. MGC-803 cells treated with and without PN were separately subjected to high-throughput RNA sequencing. Western blotting was used to investigate the expression of some important proteins.</p><p><strong>Results: </strong>Parthenolide exposure elicited cell proliferation inhibition in a doseand time-dependent manner. Parthenolide induced cell cycle arrest at the G1 and S stages. Parthenolide-induced caspase-dependent apoptosis and necroptosis were caused by the activation of RIP, RIP3 and MLKL. MGC-803 cells showed a response to ROS and oxidative stress after PN treatment. Moreover, ROS and cytotoxicity induced by PN were significantly attenuated by a ROS scavenger catalase.</p><p><strong>Conclusions: </strong>Parthenolide-induced gastric cancer cell death is a complex ROS-dependent process different from ordinary apoptosis and necrosis, suggesting that PN is a potential treatment option for gastric cancer.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1237-1245"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139401336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on regulating AQP1, AQP3, AQP4, 5-HT, NOS1 in slow transit constipation rats by Liqi Tongbian mixture. 利其通便混合物对慢速便秘大鼠AQP1、AQP3、AQP4、5-羟色胺、NOS1调节作用的研究
IF 2.1 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-11-01 DOI: 10.17219/acem/175808
Min Liu, Jianyong Chen, Chenger Zhan, Shuwen Wu, Zhaolin Zhang, Chenyang Wang, Linlin Shi, Dongya Chen

Background: Liqi Tongbian is a traditional Chinese medicine (TCM) preparation that contains herbs that may treat slow transit constipation (STC). Atractylodes macrocephala, Astragalus membranaceus, Fructus aurantii, radish seed, uncooked Polygonum multiflorum, and Agastache rugosa were included in the formula for their unique qualities. The control of water transfer in the colon is greatly influenced by aquaporin 3 (AQP3).

Objectives: Based on this, the Liqi Tongbian mixture was used to detect the concentrations of aquaporins (AQPs), 5-HT and nitrix oxide synthase 1 (NOS1) in STC rats, and explore its effect, in order to provide a theoretical basis for the remedy of STC with TCM.

Material and methods: Zhejiang University of Traditional Chinese Medicine provided 32 three-week-old Sprague Dawley rats of SPF-grade. The pairs licensed under SYXK (Zhejiang) 2021-0012 were kept at 20-25°C and humidity of 50-65%. The compound diphenoxylate caused constipation in the control, model, Liqi laxative (LQTB), and mosapride groups. The Liqi laxative rats were administered a mixture of traditional Chinese herbs after modeling, while mosapride was given to the other group. The levels of 5-HT, NOS1 and AQPs were tested in the feces and intestinal tissues.

Results: Comparing the condition of rat feces, it was found that the model group had significantly lower overall bulk, score and particles within 24 h compared to the control group. In comparison to mosapride, LQTB performed better. The model group had higher levels of 5-HT and NOS1 in intestinal tissue, while the LQTB and mosapride groups had decreased levels of these AQPs. LQTB had lower levels of AQP1, AQP3 and AQP4 than mosapride, while the model group had higher levels of these AQPs.

Conclusions: Liqi Tongbian mixture works better than mosapride in improving constipation symptoms in rats with STC, and its mechanism is related to regulating the level of intestinal AQPs and neurotransmitters.

背景:利气通便是一种传统中药制剂,含有可治疗慢传输性便秘(STC)的中草药。白术、黄芪、枳壳、萝卜子、何首乌、萹蓄因其独特的功效而被纳入方中。大肠中水分转移的控制在很大程度上受水汽蛋白 3(AQP3)的影响:在此基础上,用理气通便方检测STC大鼠体内水通道蛋白(AQPs)、5-羟色胺和一氧化氮合酶1(NOS1)的浓度,并探讨其作用,为中药治疗STC提供理论依据:浙江中医药大学提供 32 只 SPF 级三周龄 Sprague Dawley 大鼠。材料:浙江中医药大学提供 32 只 SPF 级三周龄 Sprague Dawley 大鼠,以 SYXK(浙)2021-0012 为许可证,在 20-25°C 和 50-65% 湿度条件下饲养。在对照组、模型组、利其通便剂(LQTB)组和莫沙必利组中,复方地芬诺酯都会导致便秘。利气通便组大鼠在建模后服用了中草药混合物,而另一组则服用了莫沙必利。结果显示,两组大鼠粪便和肠道组织中的 5-羟色胺、NOS1 和 AQPs 含量不同:结果:比较大鼠粪便的情况发现,模型组在 24 小时内的总体体积、分值和颗粒都明显低于对照组。与莫沙必利相比,LQTB 的效果更好。模型组肠道组织中的 5-HT 和 NOS1 水平较高,而 LQTB 组和莫沙必利组的这些 AQPs 水平较低。与莫沙必利相比,LQTB 组的 AQP1、AQP3 和 AQP4 水平较低,而模型组的这些 AQPs 水平较高:结论:在改善STC大鼠便秘症状方面,力齐通边混合物的效果优于莫沙必利,其机制与调节肠道AQPs和神经递质水平有关。
{"title":"Study on regulating AQP1, AQP3, AQP4, 5-HT, NOS1 in slow transit constipation rats by Liqi Tongbian mixture.","authors":"Min Liu, Jianyong Chen, Chenger Zhan, Shuwen Wu, Zhaolin Zhang, Chenyang Wang, Linlin Shi, Dongya Chen","doi":"10.17219/acem/175808","DOIUrl":"10.17219/acem/175808","url":null,"abstract":"<p><strong>Background: </strong>Liqi Tongbian is a traditional Chinese medicine (TCM) preparation that contains herbs that may treat slow transit constipation (STC). Atractylodes macrocephala, Astragalus membranaceus, Fructus aurantii, radish seed, uncooked Polygonum multiflorum, and Agastache rugosa were included in the formula for their unique qualities. The control of water transfer in the colon is greatly influenced by aquaporin 3 (AQP3).</p><p><strong>Objectives: </strong>Based on this, the Liqi Tongbian mixture was used to detect the concentrations of aquaporins (AQPs), 5-HT and nitrix oxide synthase 1 (NOS1) in STC rats, and explore its effect, in order to provide a theoretical basis for the remedy of STC with TCM.</p><p><strong>Material and methods: </strong>Zhejiang University of Traditional Chinese Medicine provided 32 three-week-old Sprague Dawley rats of SPF-grade. The pairs licensed under SYXK (Zhejiang) 2021-0012 were kept at 20-25°C and humidity of 50-65%. The compound diphenoxylate caused constipation in the control, model, Liqi laxative (LQTB), and mosapride groups. The Liqi laxative rats were administered a mixture of traditional Chinese herbs after modeling, while mosapride was given to the other group. The levels of 5-HT, NOS1 and AQPs were tested in the feces and intestinal tissues.</p><p><strong>Results: </strong>Comparing the condition of rat feces, it was found that the model group had significantly lower overall bulk, score and particles within 24 h compared to the control group. In comparison to mosapride, LQTB performed better. The model group had higher levels of 5-HT and NOS1 in intestinal tissue, while the LQTB and mosapride groups had decreased levels of these AQPs. LQTB had lower levels of AQP1, AQP3 and AQP4 than mosapride, while the model group had higher levels of these AQPs.</p><p><strong>Conclusions: </strong>Liqi Tongbian mixture works better than mosapride in improving constipation symptoms in rats with STC, and its mechanism is related to regulating the level of intestinal AQPs and neurotransmitters.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1209-1215"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in Clinical and Experimental Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1